We thus used the K-rasG12V oncogene because K-rasG12V is a very well-characterized oncogene, and because ras mutations are found in about 30% of the cases of pediatric MLL-rearranged AML [3]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.